UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Journal of thrombosis and haemostasis, 2004-09, Vol.2 (9), p.1594-1600

2004

Volltextzugriff (PDF)

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

BMJ (British Medical Journal), 2008-05, Vol.336 (7655), p.1227-1231

International edition, 2008

Volltextzugriff (PDF)

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

The Lancet (British edition), 2003-08, Vol.362 (9382), p.428-432

2003

Volltextzugriff (PDF)

Hormone therapy and venous thromboembolism among postmenopausal women : Impact of the route of estrogen administration and progestogens: The ESTHER study

Circulation (New York, N.Y.), 2007-02, Vol.115 (7), p.840-845

2007

Volltextzugriff (PDF)

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

European journal of epidemiology, 2013-08, Vol.28 (8), p.621-647

2013

Volltextzugriff (PDF)

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women : Impact of the route of estrogen administration

Circulation (New York, N.Y.), 2005-11, Vol.112 (22), p.3495-3500

2005

Volltextzugriff (PDF)

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

Arteriosclerosis, thrombosis, and vascular biology, 1997-11, Vol.17 (11), p.3071

1997

Volltextzugriff (PDF)

Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial

Arteriosclerosis, thrombosis, and vascular biology, 2003-09, Vol.23 (9), p.1671

2003

Volltextzugriff (PDF)

Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low-dose oral contraceptives--a preliminary report

Thrombosis and haemostasis, 1999-09, Vol.82 (3), p.1112

1999

Volltextzugriff (PDF)

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism

Journal of thrombosis and haemostasis, 2006-01, Vol.4 (1), p.71-76

2006

Volltextzugriff (PDF)

Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein

Thrombosis and haemostasis, 2003-07, Vol.90 (1), p.124

2003

Volltextzugriff (PDF)

β fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction : the ECTIM study

Circulation (New York, N.Y.), 1996-02, Vol.93 (3), p.440-449

1996

Volltextzugriff (PDF)

Safety of combined oral contraceptive pills

The Lancet (British edition), 1996-02, Vol.347 (9000), p.549

1996

Volltextzugriff (PDF)

Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study

Atherosclerosis, 2003, Vol.166 (1), p.103-109

2003

Volltextzugriff (PDF)

Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study

Atherosclerosis, 2003, Vol.166 (1), p.163-170

2003

Volltextzugriff (PDF)

Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients--the TADEUS project

Thrombosis and haemostasis, 2001-08, Vol.86 (2), p.529

2001

Volltextzugriff (PDF)

Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trial

Thrombosis and haemostasis, 1999-05, Vol.81 (5), p.673

1999

Volltextzugriff (PDF)

Thrombomodulin promoter mutations, venous thrombosis, and varicose veins

Arteriosclerosis, thrombosis, and vascular biology, 2001-03, Vol.21 (3), p.445

2001

Volltextzugriff (PDF)

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy

Drugs & aging, 1999, Vol.14 (1), p.55-61

1999

Volltextzugriff (PDF)

Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII

Arteriosclerosis, thrombosis, and vascular biology, 1996-09, Vol.16 (9), p.1170

1996

Volltextzugriff (PDF)

Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings

Maturitas, 2006-07, Vol.54 (4), p.372-379

2006

Volltextzugriff (PDF)

High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly

Haematologica (Roma), 2003-04, Vol.88 (4), p.465

2003

Volltextzugriff (PDF)

Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population

Arteriosclerosis, thrombosis, and vascular biology, 1997-05, Vol.17 (5), p.851

1997

Volltextzugriff (PDF)

Factor VII activation and oral contraceptives

Thrombosis research, 1993-05, Vol.70 (3), p.275-280

1993

Volltextzugriff (PDF)

Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME study

Atherosclerosis, 2001-08, Vol.157 (2), p.431-440

2001

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(57)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

Hormone therapy and venous thromboembolism among postmenopausal women : Impact of the route of estrogen administration and progestogens: The ESTHER study

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women : Impact of the route of estrogen administration

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial

Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low-dose oral contraceptives--a preliminary report

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism

Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein

β fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction : the ECTIM study

Safety of combined oral contraceptive pills

Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study

Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study

Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients--the TADEUS project

Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trial

Thrombomodulin promoter mutations, venous thrombosis, and varicose veins

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy

Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII

Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings

High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly

Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population

Factor VII activation and oral contraceptives

Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME study

Suchergebnisse filtern